Bio-Techne Corp Stock Research

Market Summary

USD74.19+1.76

Market Closed

2.43%

TECH Alerts

Big fall in earnings (Y/Y)

TECH Stock Price

TECH RSI Chart

TECH Valuation

Market Cap

11.7B

Price/Earnings (Trailing)

44.48

Price/Sales (Trailing)

10.41

EV/EBITDA

26.98

Price/Free Cashflow

46.25

TECH Price/Sales (Trailing)

TECH Profitability

EBT Margin

28.39%

Return on Equity

14.34%

Return on Assets

11.09%

Free Cashflow Yield

2.16%

TECH Fundamentals

TECH Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

0.86%

Revenue Q/Q

0.71%

TECH Earnings

Earnings (TTM)

262.0M

Earnings Y/Y

-37.63%

Earnings Q/Q

-44.27%

Price Action

52 Week Range

67.87113.38

(Low)(High)

Last 7 days

2.3%

Last 30 days

-1.0%

Last 90 days

-10.5%

Trailing 12 Months

-31.2%

TECH Financial Health

Current Ratio

4.4

Debt/Equity

0.11

Debt/Cashflow

1.48

TECH Investor Care

Buy Backs (1Y)

0.09%

Diluted EPS (TTM)

1.61

Peers (Alternatives to Bio-Techne)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
A	40.8B	6.8B	0.60%	4.89%	32.54	5.96	8.37%	3.64%
ILMN	36.7B	4.6B	17.13%	-33.44%	-8.34	8.02	1.28%	-677.95%
MTD	33.9B	3.9B	7.92%	11.43%	38.83	8.64	5.43%	13.46%
TECH	11.7B	1.1B	-0.96%	-31.21%	44.48	10.41	8.77%	24.82%
MID-CAP
RGEN	9.4B	801.5M	-4.54%	-10.49%	50.3	11.67	19.54%	44.95%
SMALL-CAP
PACB	2.6B	128.3M	32.04%	27.25%	-8.35	20.44	-1.69%	-73.40%
ADPT	1.3B	185.3M	8.61%	-36.38%	-6.31	6.82	20.06%	3.42%
NSTG	462.5M	127.3M	6.80%	-71.51%	-2.9	3.63	-12.28%	-38.43%
QTRX	420.1M	105.5M	6.82%	-61.39%	-4.34	3.98	-4.55%	-67.63%
BNGO	329.9M	27.8M	-14.62%	-56.98%	-2.49	11.87	54.62%	-83.06%
CDXS	272.5M	138.6M	-10.58%	-79.92%	-8.11	1.97	32.30%	-57.86%
HBIO	176.7M	113.3M	54.41%	-32.37%	-18.57	1.56	-4.68%	-3204.17%
CDXC	114.1M	72.0M	-6.71%	-37.80%	-6.91	1.58	6.82%	39.11%
CSBR	54.5M	54.1M	-13.17%	-50.55%	504.68	1.01	21.80%	-72.38%

Financials for Bio-Techne

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	0.2%	1,120	1,118	1,106	1,076	1,030
Gross Profit	0.0%	765	765	756	732	699
Operating Expenses	-1.2%	470	475	460	447	436
S&GA Expenses	-2.0%	378	386	373	363	356
EBITDA	-4.2%	433	452	414	341	-
EBITDA Margin	-4.4%	0.39*	0.40*	0.37*	0.32*	-
Earnings Before Taxes	-5.8%	318	338	301	229	206
EBT Margin	-6.0%	0.28*	0.30*	0.27*	0.21*	-
Interest Expenses	-7.1%	11.00	12.00	11.00	12.00	12.00
Net Income	-10.3%	262	292	272	225	210
Net Income Margin	-10.5%	0.23*	0.26*	0.25*	0.21*	-
Free Cahsflow	-11.4%	252	285	280	302	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	0.5%	2,363	2,351	2,295	2,300	2,305
Current Assets	2.4%	565	552	606	593	590
Cash Equivalents	-0.3%	165	165	173	161	212
Inventory	6.8%	160	150	141	128	122
Net PPE	-0.1%	224	224	223	218	212
Goodwill	0.5%	870	865	822	828	832
Current Liabilities	-6.7%	128	138	176	167	155
Long Term Debt	-24.4%	200	265	243	247	270
LT Debt, Current	0%	13.00	13.00	13.00	-	-
Shareholder's Equity	4.3%	1,827	1,751	1,702	1,714	1,703
Retained Earnings	3.2%	1,200	1,163	1,123	1,133	1,146
Additional Paid-In Capital	3.0%	701	680	652	636	616
Shares Outstanding	0.1%	157	157	157	157	157
Minority Interest	28.0%	-0.76	-1.05	-0.46	-	-
Float	-	20,300	-	-	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-11.0%	296	333	325	345	346
Share Based Compensation	6.2%	48.00	45.00	42.00	44.00	46.00
Cashflow From Investing	32.0%	-74.36	-109	-96.85	-305	-269
Cashflow From Financing	-8.0%	-253	-234	-242	-59.44	-30.60
Dividend Payments	0.0%	50.00	50.00	50.00	50.00	50.00
Buy Backs	-25.0%	139	186	161	122	86.00

Risks for TECH

What is the probability of a big loss on TECH?

61.1%

Probability that Bio-Techne stock will be more than 20% underwater in next one year

39.6%

Probability that Bio-Techne stock will be more than 30% underwater in next one year.

5.8%

Probability that Bio-Techne stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TECH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bio-Techne was unfortunately bought at previous high price.

Drawdowns

Returns for TECH

Cumulative Returns on TECH

16.9%

10-Year Cumulative Returns

18.4%

7-Year Cumulative Returns

15.0%

5-Year Cumulative Returns

16.5%

3-Year Cumulative Returns

What are the long-term rolling returns for TECH?

FIve years rolling returns for Bio-Techne.

Annualized Returns

Which funds bought or sold TECH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	ETF MANAGERS GROUP, LLC	added	3.92	95,350	545,350	0.03%
2023-03-23	MetLife Investment Management, LLC	reduced	-1.94	493,994	3,907,960	0.03%
2023-03-17	American Portfolios Advisors	reduced	-23.7	-257,695	429,692	0.02%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-3.57	730,691	6,546,690	0.01%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-0.98	228,000	1,690,000	0.01%
2023-02-28	Voya Investment Management LLC	reduced	-7.41	3,761,150	50,294,200	0.07%
2023-02-27	CASCADE INVESTMENT GROUP, INC.	new	-	331,520	331,520	0.34%
2023-02-24	SRS Capital Advisors, Inc.	added	1.4	51,447	330,447	0.05%
2023-02-24	National Pension Service	added	2.07	3,452,980	22,151,800	0.04%
2023-02-24	NATIXIS	reduced	-92.32	-970,688	95,312	-%

Latest Funds Activity

Are funds buying TECH calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own TECH

No. of Funds

TECH Alerts

Big fall in earnings (Y/Y)

Bio-Techne News

Schedule 13G FIlings of Bio-Techne

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	11.59%	18,199,432	SC 13G/A
Jan 26, 2023	blackrock inc.	10.1%	15,888,640	SC 13G/A
Jan 20, 2023	blackrock inc.	10.1%	15,888,640	SC 13G
Feb 09, 2022	vanguard group inc	11.27%	4,426,638	SC 13G/A
Jan 27, 2022	blackrock inc.	11.0%	4,328,299	SC 13G/A
Jan 25, 2022	blackrock inc.	11.0%	4,328,299	SC 13G/A
Sep 10, 2021	vanguard group inc	11.04%	4,315,543	SC 13G/A
Feb 10, 2021	vanguard group inc	9.30%	3,591,352	SC 13G/A
Jan 27, 2021	blackrock inc.	11.3%	4,348,028	SC 13G/A
Feb 12, 2020	vanguard group inc	9.36%	3,568,802	SC 13G/A

TECH Fair Value

Bio-Techne fair value in different scenarios

The table shows the Fair Value estimates for Bio-Techne for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	26.98 -63.63%	34.87 -53.00%	48.54 -34.57%	63.10 -14.95%	77.35 4.26%
Current Inflation	24.58 -66.87%	31.29 -57.82%	42.71 -42.43%	54.81 -26.12%	66.65 -10.16%
Very High Inflation	21.63 -70.85%	26.98 -63.63%	35.86 -51.66%	45.22 -39.05%	54.40 -26.67%

Historical Bio-Techne Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Bio-Techne

View All Filings

Date Filed	Form Type	Document
Mar 01, 2023	8-K	Current Report
Feb 16, 2023	UPLOAD	UPLOAD
Feb 13, 2023	CORRESP	CORRESP
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 07, 2023	10-Q	Quarterly Report
Feb 02, 2023	8-K	Current Report
Feb 02, 2023	UPLOAD	UPLOAD
Jan 31, 2023	8-K	Current Report
Jan 26, 2023	SC 13G/A	Major Ownership Report
Jan 20, 2023	SC 13G	Major Ownership Report

Latest Insider Trading transactions for TECH

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-04	Kummeth Charles R.	sold (taxes)	-21,590,100	84.39	-255,837	chief executive officer
2023-01-04	Kummeth Charles R.	acquired	10,856,300	26.65	407,364	chief executive officer
2022-12-08	Furlow Brenda S.	acquired	232,906	31.2625	7,450	svp - general counsel
2022-12-08	Furlow Brenda S.	sold	-611,810	82.1222	-7,450	svp - general counsel
2022-12-07	Furlow Brenda S.	sold	-65,605	82.0063	-800	svp - general counsel
2022-12-07	Furlow Brenda S.	acquired	25,010	31.2625	800	svp - general counsel
2022-10-27	KEEGAN JOSEPH D	acquired	-	-	338	-
2022-10-27	VESSEY RUPERT	acquired	-	-	338	-
2022-10-27	STEER RANDOLPH C	acquired	-	-	338	-
2022-10-27	BAUMGARTNER ROBERT V	acquired	-	-	338	-

About Bio-Techne

Charles R. Kummeth

www.bio-techne.com

2600

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Income Statement

2022-09-30

Condensed Consolidated Statements of Earnings and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Condensed Consolidated Statements of Earnings and Comprehensive Income
Net sales	$ 269,655	$ 257,719
Cost of sales	90,060	86,722
Gross margin	179,595	170,997
Operating expenses:
Selling, general and administrative	99,375	86,175
Research and development	23,903	21,600
Total operating expenses	123,278	107,775
Operating income	56,317	63,222
Other income (expense)	47,399	4,161
Earnings before income taxes	103,716	67,383
Income taxes (benefit)	13,982	(1,598)
Net earnings, including noncontrolling interest	89,734	68,981
Net earnings (loss) attributable to noncontrolling interest	179	(634)
Net earnings attributable to Bio-Techne	89,555	69,615
Other comprehensive income (loss):
Foreign currency translation adjustments	(21,457)	(8,646)
Foreign currency translation reclassified to earnings with Eminence deconsolidation	119
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	4,695	1,682
Other comprehensive income (loss)	(16,643)	(6,964)
Other comprehensive income (loss) attributable to noncontrolling interest	(33)	(39)
Other comprehensive income (loss) attributable to Bio-Techne	(16,610)	(6,925)
Comprehensive income attributable to Bio-Techne	$ 72,945	$ 62,690
Earnings per share attributable to Bio-Techne:
Basic	$ 2.28	$ 1.78
Diluted	$ 2.21	$ 1.69
Weighted average common shares outstanding:
Basic	39,232	39,094
Diluted	40,543	41,158

TECH Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Current assets:
Cash and cash equivalents	$ 165,257	$ 172,567
Short-term available-for-sale investments	37,818	74,462
Accounts receivable, less allowance for doubtful accounts of $2,496 and $2,568, respectively	174,174	194,548
Inventories	150,009	141,123
Other current assets	24,773	22,856
Total current assets	552,031	605,556
Property and equipment, net	224,098	223,242
Right of use asset	69,745	65,556
Goodwill	865,418	822,101
Intangible assets, net	585,534	531,522
Other assets	53,895	46,828
Total assets	2,350,721	2,294,805
Current liabilities:
Trade accounts payable	30,475	33,865
Salaries, wages and related accruals	32,557	61,953
Accrued expenses	13,790	17,886
Contract liabilities	22,059	23,406
Income taxes payable	17,270	13,237
Operating lease liabilities - current	12,115	11,928
Contingent consideration payable	7,400
Current portion of long-term debt obligations		12,500
Other current liabilities	1,963	1,243
Total current liabilities	137,629	176,018
Deferred income taxes	112,920	98,994
Long-term debt obligations	264,661	243,410
Long-term contingent consideration payable	8,100	5,000
Operating lease liabilities	64,756	58,133
Other long-term liabilities	11,501	12,239
Bio-Techne's Shareholders' equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	0	0
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,232,094 and 39,160,000, respectively	392	392
Additional paid-in capital	680,057	653,657
Retained earnings	1,162,515	1,122,921
Accumulated other comprehensive loss	(91,810)	(75,200)
Total Bio-Techne's shareholders' equity	1,751,154	1,701,770
Noncontrolling interest		(759)
Total shareholders' equity	1,751,154	1,701,011
Total liabilities and shareholders' equity	$ 2,350,721	$ 2,294,805